Third Harmonic Bio Inc.

NASDAQ THRD

Data sourced from

and

Download Data

Third Harmonic Bio Inc. Cash Return on Equity (CROE) 5 year CAGR for the year ending December 31, 2023

Third Harmonic Bio Inc. Cash Return on Equity (CROE) 5 year CAGR is NA for the year ending December 31, 2023. The cash return on equity ratio measures the profitability of a company's shareholders' equity based on its operating cash flow. It is calculated by dividing operating cash flow by shareholders' equity. This ratio provides insight into how effectively the company generates cash flow in relation to the shareholders' investment. A higher ratio indicates better cash flow generation relative to the equity invested. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Third Harmonic Bio Inc. Cash Return on Equity (CROE) for the year ending December 31, 2022 was -0.12, a -135.83% change year over year.
Third Harmonic Bio Inc. Cash Return on Equity (CROE) for the year ending December 31, 2021 was 0.34, a -32.64% change year over year.
Third Harmonic Bio Inc. Cash Return on Equity (CROE) for the year ending December 31, 2020 was 0.50.

NASDAQ: THRD

Third Harmonic Bio Inc.

CEO	Ms. Natalie C. Holles
IPO Date	Sept. 14, 2022
Location	United States
Headquarters	300 Technology Square, Cambridge, MA, United States, 02139
Employees	31
Sector	Healthcare
Industry	Biotechnology

Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Key trends